Targeted pill trial aims to control advanced cancers driven by rogue genes
NCT ID NCT04189445
Summary
This study tested an experimental pill called futibatinib in people with advanced cancers that have specific changes in genes called FGFR. It enrolled 115 patients into three groups based on their cancer type and specific gene change. The goal was to see if the daily pill could shrink tumors and control the disease, and to understand its safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acibadem Adana Hospital
Adana, 01130, Turkey (Türkiye)
-
Acibadem Maslak Hospital
Istanbul, 34457, Turkey (Türkiye)
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
-
Akademiska Sjukhuset
Uppsala, 75185, Sweden
-
Antoni van Leeuwenhoek
Amsterdam, 1066 CX, Netherlands
-
Asan Medical Center
Seoul, 05505, South Korea
-
Azienda Ospedaliera Universitaria Careggi
Florence, 50134, Italy
-
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Trento)
Verona, 37124, Italy
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234-2165, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215-5400, United States
-
Centre Antoine Lacassagne
Nice, Alpes Maritimes, 06200, France
-
Centre Georges François Leclerc
Dijon, Côte-d'Or, 21079, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, Rhone, 69495, France
-
Centre Léon Bérard
Lyon, Rhone, 69008, France
-
Centre Paul Strauss
Strasbourg, Bas Rhin, 67000, France
-
Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos
Lisbon, 1169-050, Portugal
-
Centro Hospitalar do Porto, E.P.E - Hospital de Santo Antonio
Porto, 4099-001, Portugal
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Erasmus Medisch Centrum
Rotterdam, 3015 AA, Netherlands
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 53705, United States
-
Fundação Champalimaud
Lisbon, 4099-001, Portugal
-
Georgetown University - Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Henry Ford Hospital
Woodhaven, Michigan, 48183, United States
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
Hong Kong United Oncology Centre
Jordon, 0000, Hong Kong
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario HM Madrid Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
-
Hôpital Saint-Louis
Paris, Paris, 75475, France
-
IEO Istituto Europeo di Oncologia
Milan, 20141, Italy
-
Institut Bergonié
Bordeaux, Gironde, 33076, France
-
Institut Gustave Roussy
Villejuif, Val De Marne, 94805, France
-
Institut Jules Bordet
Brussels, 1000, Belgium
-
Instituto Valenciano de Oncologia IVO
Valencia, 46009, Spain
-
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
Meldola, Forli - Cesena, 47014, Italy
-
Karolinska universitetssjukhuset - Solna
Solna, 171 64, Sweden
-
Mercy Clinic Oncology and Hematology - Coletta
Oklahoma City, Oklahoma, 73120, United States
-
NHO Shikoku Cancer Center
Matsuyama, Ehime, 791-0280, Japan
-
Namik Kemal University
Tekirdağ, 59100, Turkey (Türkiye)
-
National Cancer Center Hospital
Chūōku, Tokyo-To, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
National University Cancer Institute
Singapore, 119074, Singapore
-
Osaka University Hospital
Suita-shi, Osaka, 565-0871, Japan
-
Ospedale Sacro Cuore Don Calabria
Negrar, Verona, 37024, Italy
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sarah Cannon Research Institute UK
London, Greater London, W1G 6AD, United Kingdom
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
The University of Hong Kong
Hong Kong, Hong Kong
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCLA Medical Center
Los Angeles, California, 90404, United States
-
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Universitaetsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, 69120, Germany
-
Universitaetsklinikum Koeln
Cologne, North Rhine-Westphalia, 50924, Germany
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.